Better Health for All

Surmodics' core products demonstrate significant health benefits. The SurVeil™ DCB, with a lower paclitaxel dose (2.0 μg/mm2) compared to a market-leading device (3.5 μg/mm2), showed comparable safety and efficacy for femoropopliteal arterial disease (PAD) in the TRANSCEND trial.

Additionally, the company's vascular intervention tools, such as the Sublime™ 5 Fr Radial Access Guide Sheath (diameter less than 2.4 millimeters), improve PAD treatment by offering a safer radial access method, particularly beneficial for women with smaller radial arteries. However, the company's safety record shows notable incidents. An FDA safety letter from November 2015 highlighted 11 product recalls, 500 adverse event reports, and 9 deaths related to flaking hydrophilic coatings on medical wires, a technology area Surmodics operates in. More recently, in November 2021, a MAUDE report detailed one adverse event involving minor vessel damage during clot removal using the SURMODICS, INC POUNCE Thrombus Retrieval System. The company's instructions for use (IFU) for this device include contraindications and warnings. The TRANSCEND trial for the SurVeil™ DCB involved 446 patients across 65 sites in 9 countries, with a 5-year follow-up plan, indicating a commitment to comprehensive data collection.

Fair Pay & Worker Respect

The company's employee rating is 3.4 out of 5 stars based on 48 reviews, which translates to 68% engagement.

This rating is in line with the average for employers in the Manufacturing industry (3.5 stars). 56% of employees would recommend working at Surmodics to a friend, and 64% approve of the CEO. However, the company laid off approximately 13% of its workforce, affecting nearly 60 workers, with one-time severance costs between $1 million and $1.2 million. Employee reviews also mention frequent turnovers and layoffs, with some employees being laid off without advance notice. Furthermore, the company was involved in an FTC lawsuit regarding an unlawful acquisition. Some employees have also reported being on contract, indicating a portion of the workforce may be on insecure contracts.

Fair Trade & Ethical Sourcing

No information was provided in the articles regarding Surmodics, Inc.'s fair trade certifications, supplier audit frequency, incidents of forced or child labor, supply chain traceability, remediation speed for violations, ethical clauses in supplier contracts, share of high-risk materials, or supplier diversity spend.

The articles focused on general business overview and environmental sustainability efforts related to waste management and energy efficiency, which do not provide data relevant to the 'Fair Trade & Ethical Sourcing' KPIs.

Honest & Fair Business

Surmodics, Inc. has a Code of Ethics and Business Conduct, dated August 2022, which applies to all locations, affiliates, and subsidiaries.

This code includes an anti-corruption policy that prohibits bribes, kickbacks, and improper payments to government officials, customers, and healthcare providers, both directly and indirectly. It also details specific prohibitions on gifts and entertainment for government officials and U.S. healthcare professionals, requiring consultation with legal staff for international contexts. The company also has a whistleblower policy, establishing an anonymous hotline (1-800-338-9081) and website (secure.ethicspoint.com) for reporting concerns, with a prohibition against retaliation. However, there is no evidence of independent investigation processes for these reports. Waivers of the Code for executive officers or directors can only be granted by the Board of Directors, with only independent members voting, or by an appropriate Board committee consisting of independent directors, and must be promptly disclosed to shareholders. No information was found regarding regulatory fines, transparency index scores, financial restatements, audit coverage, ESG controversy index, complaint resolution times, or third-party verification of ethical claims.

Kind to Animals

Surmodics, Inc. is identified as a company that uses animal testing.

An acute animal GLP study was conducted for the Thrombus Retrieval System device to evaluate its performance and safety. However, no animal testing data was required for the Pounce Sheath device. The company used 15,000 animals in testing in 2023.

No War, No Weapons

Surmodics, Inc. reported that conflict minerals (tin, tantalum, tungsten, and gold) comprise less than a fraction of a percent of its final device products for the period of January 1, 2024, to December 31, 2024.

These minerals were sourced from "certified smelters and legitimate mines, according to RM ‘Conformant Smelters-list’". The company uses the Responsible Minerals Initiative (RMI) Conflict Minerals Reporting Template (CMRT) for due diligence. For a chemical compound derived from tin, the company concluded there was no reason to believe it originated in a Covered Country and conducted a country of origin inquiry.

Planet-Friendly Business

Surmodics uses 22% renewable energy for its operations.

The company achieved 100% compliance with EPA and FDA environmental regulations in 2023, passing all four environmental audits, and reported zero violations. In 2023, Surmodics reduced waste by 12.3 metric tons. The company's 'Zero Project,' launched in February 2021, resulted in 25.5 tonnes of carbon savings from LED lighting and 0.6 tonnes from an electric lawnmower, with 95% of lights automatically switching off via sensors.

Safe & Smart Tech

Surmodics experienced a cyber incident on June 5, 2025, involving unauthorized third-party access to its IT systems, which were taken offline for containment.

The company reported the incident to the SEC and notified law enforcement. While the extent of data exfiltration is unknown and data validation is ongoing, the company believes no data has been released or used fraudulently, and no such release or fraudulent use has been reported. The company's privacy policy states that users have the right to correct, update, delete their information, and unsubscribe from communications. The company has disclosed the cyber incident to the SEC, and potential regulatory activity is mentioned as a risk, indicating a reactive approach to regulatory scrutiny following an incident.